-

10:52:59 AM

EDSA Stock News

EDSA - Edesa Biotech Inc

08/03/22 8:15 AM

Nasdaq : EDSA

conferenceslow float

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held in

RHEA-AI

neutral

07/11/22 8:30 AM

Nasdaq : EDSA

conferenceslow float

Edesa Biotech to Present at ARDS Drug Development Summit

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development Summit

RHEA-AI

neutral

05/24/22 7:55 AM

Nasdaq : EDSA

clinical triallow float

Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Phase 2/3

RHEA-AI

negative

05/19/22 4:30 PM

Nasdaq : EDSA

conferenceslow float

Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global

RHEA-AI

neutral

05/13/22 8:55 AM

Nasdaq : EDSA

earningslow float

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 and provided an update on its business. For

RHEA-AI

positive

04/28/22 7:45 AM

Nasdaq : EDSA

low float

Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory

RHEA-AI

neutral

03/29/22 9:00 AM

Nasdaq : EDSA

managementlow float

Edesa Biotech Appoints Strategy Expert to Board of Directors

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors. "Ms. Chao's appointment to our

RHEA-AI

neutral

03/24/22 4:30 PM

Nasdaq : EDSA

offeringlow float

Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules

RHEA-AI

neutral

03/22/22 8:00 AM

Nasdaq : EDSA

offeringlow float

Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for

RHEA-AI

neutral

02/17/22 8:00 AM

Nasdaq : EDSA

clinical triallow float

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody

RHEA-AI

neutral

EDSA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.edesabiotech.com
Security nameEdesa Biotech Inc
Issue typecs
SectorManufacturing
Sic code2834
Tags
- Biotechnology
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Edesa Biotech Inc

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that it's developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.